======= TUT1 ======= == Gene Information == * **Official Symbol**: TUT1 * **Official Name**: terminal uridylyl transferase 1, U6 snRNA-specific * **Aliases and Previous Symbols**: N/A * **Entrez ID**: [[https://www.ncbi.nlm.nih.gov/gene/?term=64852|64852]] * **UniProt**: [[https://www.uniprot.org/uniprot/Q9H6E5|Q9H6E5]] * **Interactions**: [[https://thebiogrid.org/search.php?search=TUT1&organism=9606|BioGRID]] * **PubMed articles**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20TUT1|Open PubMed]] * **OMIM**: [[https://omim.org/entry/610641|Open OMIM]] == Function Summary == * **Entrez Summary**: N/A * **UniProt Summary**: Poly(A) polymerase that creates the 3'-poly(A) tail of specific pre-mRNAs. Localizes to nuclear speckles together with PIP5K1A and mediates polyadenylation of a select set of mRNAs, such as HMOX1. In addition to polyadenylation, it is also required for the 3'-end cleavage of pre-mRNAs: binds to the 3'UTR of targeted pre-mRNAs and promotes the recruitment and assembly of the CPSF complex on the 3'UTR of pre-mRNAs. In addition to adenylyltransferase activity, also has uridylyltransferase activity. However, the ATP ratio is higher than UTP in cells, suggesting that it functions primarily as a poly(A) polymerase. Acts as a specific terminal uridylyltransferase for U6 snRNA in vitro: responsible for a controlled elongation reaction that results in the restoration of the four 3'-terminal UMP-residues found in newly transcribed U6 snRNA. Not involved in replication- dependent histone mRNA degradation. {ECO:0000269|PubMed:16790842, ECO:0000269|PubMed:18288197, ECO:0000269|PubMed:21102410}. |PAP assoc| |RRM 1| |RNA uridylyltransferase activity| |polynucleotide adenylyltransferase activity| |pre-mRNA cleavage required for polyadenylation| |mRNA cleavage involved in mRNA processing| |histone mRNA catabolic process| |mRNA cleavage and polyadenylation specificity factor complex| |mRNA cleavage| |mRNA polyadenylation| |histone mRNA metabolic process| |RNA polyadenylation| |snRNA processing| |snRNA metabolic process| |mRNA 3-UTR binding| |mRNA 3-end processing| |RNA 3-end processing| |RNA phosphodiester bond hydrolysis| |nuclear-transcribed mRNA catabolic process| |mRNA catabolic process| |RNA catabolic process| |nucleic acid phosphodiester bond hydrolysis| |enzyme binding| |nucleobase-containing compound catabolic process| |ncRNA processing| |nuclear speck| |heterocycle catabolic process| |cellular nitrogen compound catabolic process| |aromatic compound catabolic process| |ncRNA metabolic process| |mRNA processing| |organic cyclic compound catabolic process| |mRNA metabolic process| |nucleolus| |RNA processing| |cellular macromolecule catabolic process| |macromolecule catabolic process| |RNA binding| |ATP binding| |RNA metabolic process| |negative regulation of gene expression| |organic substance catabolic process| |cellular catabolic process| |gene expression| \\ === CRISPR Data === ^Screen^Score^ |[[:results:exp453|B02 10μM R08 exp453]]|-2.2| |[[:results:exp75|MK-1775 0.32μM R02 exp75]]|-2.08| |[[:results:exp351|Dexamethasone 0.006μM R07 exp351]]|-2.03| |[[:results:exp287|HMS-I2 5μM R06 exp287]]|-1.89| |[[:results:exp97|BI-6727 0.0125μM R03 exp97]]|-1.86| |[[:results:exp318|ABT-702 5μM R07 exp318]]|-1.82| |[[:results:exp60|Vinblastine 0.002μM R01 exp60]]|-1.75| |[[:results:exp229|Dimethyloxaloylglycine 100μM R05 exp229]]|-1.73| |[[:results:exp475|CyclicAMP 200μM R08 exp475]]|-1.71| |[[:results:exp335|Aminopterin 0.005μM R07 exp335]]|1.76| |[[:results:exp240|Pyridostatin 4μM R05 exp240]]|1.79| |[[:results:exp259|6-Thio-2-deoxyguanosine 2μM R06 exp259]]|2.4| ^Gene^Correlation^ |[[:human genes:c:cd2bp2|CD2BP2]]|0.598| |[[:human genes:h:hars|HARS]]|0.5| |[[:human genes:n:n6amt1|N6AMT1]]|0.439| |[[:human genes:s:snapc5|SNAPC5]]|0.437| |[[:human genes:n:ncdn|NCDN]]|0.423| |[[:human genes:a:aar2|AAR2]]|0.412| |[[:human genes:p:ppp6c|PPP6C]]|0.402| Global Fraction of Cell Lines Where Essential: 699/739 ^Tissue^Fraction Of Cell Lines Where Essential^ |1290807.0|1/1| |909776.0|1/1| |bile duct|27/28| |blood|24/28| |bone|25/26| |breast|32/33| |central nervous system|51/56| |cervix|4/4| |colorectal|16/17| |esophagus|13/13| |fibroblast|1/1| |gastric|16/16| |kidney|21/21| |liver|19/20| |lung|73/75| |lymphocyte|16/16| |ovary|22/26| |pancreas|22/24| |peripheral nervous system|15/16| |plasma cell|15/15| |prostate|1/1| |skin|23/24| |soft tissue|9/9| |thyroid|2/2| |upper aerodigestive|20/22| |urinary tract|27/29| |uterus|5/5| == Essentiality in NALM6 == * **Essentiality Rank**: 862 * **Expression level (log2 read counts)**: 4.84 {{:chemogenomics:nalm6 dist.png?nolink |}}